WO2003074479A1 - Semicarbazidderivate und ihre verwendung als antithrombotika - Google Patents
Semicarbazidderivate und ihre verwendung als antithrombotika Download PDFInfo
- Publication number
- WO2003074479A1 WO2003074479A1 PCT/EP2003/001177 EP0301177W WO03074479A1 WO 2003074479 A1 WO2003074479 A1 WO 2003074479A1 EP 0301177 W EP0301177 W EP 0301177W WO 03074479 A1 WO03074479 A1 WO 03074479A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- solvates
- compounds
- formula
- stereoisomers
- mixtures
- Prior art date
Links
- 0 C*c1n[o]c(C)n1 Chemical compound C*c1n[o]c(C)n1 0.000 description 1
- RKRLQDJTVWZXMM-UHFFFAOYSA-N CC(N1)=NOC1=O Chemical compound CC(N1)=NOC1=O RKRLQDJTVWZXMM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
- C07C281/06—Compounds containing any of the groups, e.g. semicarbazides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/47—Y being a hetero atom
Definitions
- the invention relates to compounds of the formula
- R 2 is simply phenyl substituted by S (0) p A, S (0) p NHA, CF 3 , COOA or CH 2 NHA, R 3 H or shark,
- Ar unsubstituted or single, double or triple by A, OH, OA, NH 2 , NHA, NA 2 , N0 2 , CF 3 , CN, shark, COA, NHCOA, COOA, CONH 2 , CONHA, CONA 2 , S (0) p A, S (0) p NH 2 , S (0) p NHA,
- the object of the invention was to find new compounds with valuable properties, in particular those which can be used for the production of medicaments.
- the compounds of the formula I and their salts have very valuable pharmacological properties with good tolerability.
- they show factor Xa inhibitory properties and can therefore be used to combat and prevent thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis,
- Inflammation apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication can be used.
- the compounds of the formula I according to the invention can furthermore be inhibitors of the coagulation factors factor VIIa, factor IXa and thrombin of the blood coagulation cascade.
- Aromatic amidine derivatives with antithrombotic activity are e.g. from EP 0 540 051 B1, WO 98/28269, WO 00/71508, WO 00/71511, WO
- Cyclic guanidines for the treatment of thromboembolic diseases are e.g. described in WO 97/08165.
- Aromatic heterocycles with factor Xa inhibitory activity are e.g. known from WO 96/10022.
- Substituted N - [(aminoiminomethyl) phenylalkyl] azaheterocyclylamides as factor Xa inhibitors are in WO
- the antithrombptic and anticoagulant effect of the compounds according to the invention is attributed to the inhibitory action against the activated coagulation protease, known under the name factor Xa, or to the inhibition of other activated serine proteases such as factor VIII, factor IXa or thrombin.
- Factor Xa is one of the proteases involved in the complex process of blood clotting. Factor Xa catalyzes the conversion of
- thromboembolic Prothrombin in thrombin. Thrombin cleaves fibrinogen into fibrin monomers which, after cross-linking, make an elementary contribution to thrombus formation. Activation of thrombin can lead to the occurrence of thromboembolic
- Inhibit thrombus formation involved fibrin formation.
- the inhibition of thrombin can be measured, for example, by the method of GF Cousins et al. in Circulation 1996, 94, 1705-1712.
- Inhibition of factor Xa can thus prevent thrombin from being formed.
- the compounds of formula I according to the invention and their salts interfere with the blood coagulation process by inhibiting factor Xa and thus inhibit the formation of thrombi.
- the inhibition of factor Xa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be determined by customary in vitro or in vivo methods.
- a suitable method is e.g. by J. Hauptmann et al. in Thrombosis and Haemostasis 1990, 63, 220-223.
- the measurement of the inhibition of factor Xa can e.g. using the method of T. Hara et al. in thromb. Haemostas. 1994, 71, 314-319.
- the coagulation factor VIa initiates the extrinsic part of the coagulation cascade after binding to the tissue factor and contributes to the activation of the factor X to factor Xa. Inhibition of factor VIIa thus prevents the formation of factor Xa and thus the subsequent formation of thrombin.
- the inhibition of the factor VIIa by the compounds according to the invention and the measurement of the anticoagulant and antithrombotic activity can be carried out according to customary in vitro or in vivo methods.
- Coagulation factor IXa is generated in the intrinsic coagulation cascade and is also involved in the activation of factor X to factor Xa. Inhibition of factor IXa can therefore otherwise prevent factor Xa from being formed.
- the compounds according to the invention can furthermore be used for the treatment of tumors, tumor diseases and / or tumor metastases.
- Tumor types K.M. Donnelly et al. in thromb. Haemost. 1998; 79: 1041-1047;
- the compounds of formula I can be used as active pharmaceutical ingredients in human and veterinary medicine, in particular for the treatment and prevention of thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudication intermittent, venous thrombosis, pulmonary embolism, arterial thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudication intermittent, venous thrombosis, pulmonary embolism, arterial thromboembolic disorders such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudication intermittent, venous thrombosis, pulmonary embolism, arterial thromboembolic disorders such as thro
- Thrombosis myocardial ischemia, unstable angina and thrombosis-based stroke.
- the compounds of the invention are also used for treatment or
- the compounds are also used in combination with other thrombolytics for myocardial infarction, and also for prophylaxis
- the compounds according to the invention are also used for the prevention of rethrombosis in microsurgery, furthermore as
- the compounds are also used in the cleaning of
- Blood coagulation contributes significantly to the course of the disease or is a source of secondary pathology, such as cancer including metastasis, inflammatory diseases including
- the compounds of the invention are also used to treat migraines (F. Morales-Asin et al., Headache, 40, 2000, 45-47).
- the compounds according to the invention are also used in combination with other thrombolytically active compounds, such as, for example, with the "Tissue plasminogen activator" t-PA, modified t-PA, streptokinase or urokinase.
- t-PA tissue plasminogen activator
- modified t-PA modified t-PA
- streptokinase or urokinase.
- urokinase urokinase
- the simultaneous administration with aspirin is particularly preferred
- the invention relates to the compounds of the formula I and their salts and to a process for the preparation of compounds of the formula I according to claims 1-9 and their pharmaceutically usable
- the invention also relates to the optically active forms
- Solvates are e.g. Mono- or dihydrates or
- compositions are e.g. the salts of the compounds according to the invention and also so-called prodrug compounds.
- Prodrug derivatives are understood with z. B. alkyl or acyl groups, sugars or oligopeptides modified compounds of formula I, which are quickly cleaved in the organism to the active compounds of the invention.
- This also includes biodegradable polymer derivatives of the compounds according to the invention, as described, for. B. in Int. J. Pharm. 115. 61-67 (1995).
- the invention also relates to mixtures of the compounds of the formula I according to the invention, e.g. Mixtures of two diastereomers e.g. in a ratio of 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1: 10, 1: 100 or 1: 1000. These are particularly preferably mixtures of stereoisomeric compounds.
- X represents alkyl, is unbranched (linear), branched or cyclic, and has
- X is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, further also pentyl, 1-, 2-
- X very particularly preferably denotes alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, cyclopentyl , Cyclohexyl, trifluoromethyl, pentafluoroethyl or 1, 1, 1-trifluoroethyl.
- Cyclic alkyl preferably means cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.
- a means alkyl is unbranched (linear), branched or cyclic, and has 5 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 , 18, 19 or 20
- A is preferably methyl, furthermore ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl, furthermore also pentyl, 1-, 2- or 3-methylbutyl, 1, 1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl, 0 hexyl, 1-, 2-, 3- or 4-methylpentyl, 1, 1-, 1, 2-, 1, 3-, 2,2-, 2,3 - or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1, 1, 2- or 1, 2,2-trimethylpropyl, more preferably for example Trifluoromethyl.
- Alkylene preferably means methylene, ethylene, propylene, butylene,
- -COA acyl
- acyl preferably means acetyl, propionyl, but also butyryl
- Pentanoyl hexanoyl or e.g. Benzoyl.
- the invention also relates in particular to those by -COA,
- R preferably denotes amidino, which can also be substituted by OH or CH 2 NH 2 .
- R 1 preferably denotes phenyl, benzyl or alkyl having 1, 2, 3, 4, 5, 6 or 7 carbon atoms,
- R 2 preferably denotes a phenyl radical which is simply substituted by alkylsulfonyl [S (0) 2 A] or aminosulfonyl [S (0) 2 NHA], the substituents S0 2 CH 3 or S0 2 NH 2 being particularly preferred.
- R 3 is preferably H or F.
- Ar means e.g. unsubstituted phenyl, further preferably e.g. by A, fluorine, chlorine, bromine, iodine, hydroxy, methoxy, ethoxy, propoxy, butoxy, pentyloxy, hexyloxy, nitro, cyano, formyl, acetyl, propionyl, trifluoromethyl, amino, methylamino, ethylamino, dimethylamino, diethylamino, sulfonamido, methylsulfonamido , Ethylsulfonamido, propylsulfonamido, butylsulfonamido, dimethylsulfonamido, phenylsulfonamido, carboxy, methoxycarbonyl, ethoxycarbonyl or phenyl mono-, di- or tri-substituted by aminocarbonyl.
- Ar very particularly
- Het means, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrrolyl, 1-, 2, 4- or 5-imidazolyl, 1-, 3-, 4- or 5- Pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3-, 4- or 5- Isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, further preferably 1, 2,3-triazo -, -4- or -5-yl, 1, 2,4 Triazol-1-, -3- or 5-yl, 1- or 5-tetrazolyl, 1, 2,3-oxadiazol-4- or -5-yl, 1, 2,4-oxadiazol-3- or -
- 5-, 6- or 7- benzisoxazolyl 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz-2,1, 3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-cinnolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5- or 6- Quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo [1, 4] oxazinyl, more preferably 1, 3-benzodioxol-5-yl, 1, 4-benzodioxan-6-yl , 2,1, 3-benzothiaediazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.
- the heterocyclic radicals can also be partially or completely hydrogenated.
- Het can, for. B. also mean 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-, -4- or 5-furyl, tetrahydro-2 - or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 2,5-dihydro-1-, -2-, -3-, -4- or -5-pyrrolyl, 1-, 2- or 3-pyrrolidinyl, tetrahydro-1-, -2 - or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4- or -5-pyrazolyl, tetrahydro-1-, -3- or -4-pyrazolyl, 1, 4
- Het preferably means a mononuclear saturated or unsaturated heterocycle having 1 to 2 N and / or O atoms, which can be unsubstituted or mono- or disubstituted by A.
- Het very particularly preferably denotes pyridyl, pyrimidinyl, morpholin-4-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-1-yl or oxazolidin-3-yl.
- the compounds of the formula I can have one or more chiral centers and therefore exist in various stereoisomeric forms.
- Formula I encompasses all of these forms.
- the invention relates in particular to those compounds of the formula I in which at least one of the radicals mentioned has one of the preferred meanings indicated above.
- Some preferred groups of compounds can be expressed by the following sub-formulas la to le, which correspond to the formula I and in which the radicals not specified have the meaning given for the formula I, but in which
- Ic R 3 is H or F; in Id R 2 denotes a phenyl radical which is simply substituted by alkylsulfonyl or aminosulfonyl;
- R 2 denotes a phenyl radical which is simply substituted by methylsulfonyl or aminosulfonyl;
- the starting materials can also be formed in situ, so that they are not isolated from the reaction mixture, but instead are immediately reacted further to give the compounds of the formula I.
- Compounds of formula I can preferably be obtained by liberating compounds of formula I from one of their functional derivatives by treatment with a solvolysing or hydrogenolysing agent.
- Preferred starting materials for solvolysis or hydrogenolysis are those which otherwise correspond to the formula I but which correspond to one or more free amino and / or hydroxyl groups
- Protected amino and / or hydroxyl groups contain, preferably those which, instead of an H atom which is connected to an N atom, carry an amino protective group, in particular those which instead of one
- HN group carry an R'-N group, in which R 'represents an amino protecting group 5 and / or those which carry a hydroxyl protecting group instead of the H atom of a hydroxyl group, e.g. those which correspond to the formula I, but instead of a group -COOH carry a group -COOR "in which R" denotes a hydroxyl protective group.
- Preferred starting materials are also the oxadiazole derivatives, which can be converted into the corresponding amidino compounds.
- the release of the amidino group from its oxadiazole derivative can e.g. A C can be split off by treatment with hydrogen in the presence of a catalyst (e.g. Raney nickel).
- a catalyst e.g. Raney nickel
- Suitable solvents are those specified below, in particular alcohols such as methanol or ethanol, organic acids such as acetic acid or propionic acid or mixtures thereof.
- the hydrogenolysis is generally carried out at 0 temperatures between about 0 and 100 ° and pressures between about 1 and 200 bar, preferably at 20-30 ° (room temperature) and 1-10 bar. 5
- the introduction of the oxadiazole group succeeds e.g. by reaction of the cyan compounds with hydroxylamine and reaction with phosgene, dialkyl carbonate, chloroformate, N, N'-carbonyldiimidazole or acetic anhydride. 0
- amino protecting group is generally known and refers to groups which are suitable for protecting (blocking) an amino group from chemical reactions, but which are easily removable after the desired chemical reaction at other locations on the
- Unsubstituted or substituted acyl, aryl, aralkoxymethyl or aralkyl groups are particularly typical of such groups. Since the amino protecting groups are removed after the desired reaction (or reaction sequence), their type and size is im
- acyl group is to be understood in the broadest sense in connection with the present process. It encompasses aliphatic, araliphatic, aromatic or hetero-
- acyl groups are alkanoyl such as acetyl, propionyl, butyryl; Aralkanoyl such as phenylacetyl; Aroyl such as benzoyl or toluyl; Aryloxyalkanoyl such as POA; Alkoxycarbonyl such as methoxycarbonyl, ethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, BOG (tert-butyloxycarbonyl), 2-iodoethoxycarbonyl; Aralkyloxycarbonyl such as CBZ ("carbobenzoxy”), 4-methoxybenzyloxycarbonyl, FMOC; Arylsulfonyl such as Mtr.
- Preferred amino protective groups are BOC and Mtr, furthermore
- hydroxyl protecting group is also generally known and refers to groups which are suitable for protecting a hydroxyl group against chemical reactions, but which are easily removable after the desired chemical reaction has been carried out elsewhere in the molecule. Typical of such groups are the unsubstituted or substituted aryl, aralkyl or
- hydroxy protecting groups include Benzyl, 4-methoxybenzyl, p-nitrobenzoyl, p-
- Suitable inert solvents are preferably organic, for example carboxylic acids such as acetic acid, ethers such as tetrahydrofuran or dioxane, amides such as DMF, halogenated hydrocarbons such as dichloromethane, and also alcohols such as methanol, ethanol or isopropanol, and water. Mixtures of the abovementioned solvents are also suitable. TFA is preferably used in excess without the addition of another solvent, perchloric acid in the form of a mixture of acetic acid and 70% perchloric acid in a ratio of 9: 1.
- the reaction temperatures for the cleavage are advantageously between about 0 and about 50 °, preferably between 15 and 30 ° (room temperature).
- the groups BOC, OBut and Mtr can e.g. B. preferably with TFA in dichloromethane or with about 3 to 5N HCl in dioxane at 15-30 °, the FMOC group with an about 5 to 50% solution of dimethylamine, diethylamine or piperidine in DMF at 15th -30 °.
- Protective groups which can be removed hydrogenolytically can, for. B. by treatment with hydrogen in the presence of a catalyst (z. B. a noble metal catalyst such as palladium, advantageously on a support such as coal).
- Suitable solvents are the above, especially z. B. alcohols such as methanol or
- Hydrogenolysis of the CBZ group succeeds e.g. B. good on 5 to 10% Pd / C in methanol or with ammonium formate (instead of hydrogen) on Pd / C in methanol / DMF at 20-30 °.
- Suitable inert solvents are e.g. Hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; chlorinated hydrocarbons such as trichlorethylene, 1, 2-dichloroethane, carbon tetrachloride,
- Trifluoromethylbenzene, chloroform or dichloromethane Trifluoromethylbenzene, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether (methyl glycol or ethyl glycol), ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide, N-methylpyrrolidone (NMP) or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulphide; Carboxy
- Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate or mixtures of the solvents mentioned.
- the conversion of a cyano group into an amidino group takes place by reaction with e.g. Hydroxylamine and subsequent reduction of the N-hydroxyamidine with hydrogen in the presence of a catalyst such as e.g. Pd / C.
- a catalyst such as e.g. Pd / C.
- a nitrile can also be used to prepare an amidine of the formula I
- Add ammonia is preferably carried out in several stages by, in a manner known per se, a) the nitrile with H 2 S in a thioamide converts, which is converted with an alkylating agent, for example CH 3 I, into the corresponding S-alkyl imidothioester, which in turn reacts with NH 3 to give the amidine, b) the nitrile with an alcohol, for example ethanol in the presence of HCl, in the corresponding imido ester 5 converted and treated with ammonia (Pinner synthesis), or c) reacting the nitrile with lithium bis (trimethylsilyl) amide and then hydrolyzing the product.
- an alkylating agent for example CH 3 I
- esters can e.g. with acetic acid or with NaOH or KOH in water,
- Water THF or water dioxane can be saponified at temperatures between 0 and 100 °.
- an inert solvent such as dichloromethane or THF
- a base such as triethylamine or pyridine 0 at temperatures between -60 and + 30 °.
- a base of the formula I can be converted with an acid into the associated acid addition salt, for example by reacting equivalent amounts of the base and the acid in an inert solvent such as ethanol and subsequent evaporation.
- acids that provide physiologically acceptable salts are suitable for this implementation.
- inorganic acids can be used, for example Q sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric acid, sulfamic acid, and also organic acids, in particular aliphatic, alicyclic, araliphatic, aromatic or heterocyclic mono- or poly-based carbon, sulfonic or sulfuric acids, for example 5 formic acid, acetic acid, propionic acid, pivalic acid, diethyl acetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, Lactic acid, tartaric acid, malic acid, citric acid, gluconic acid, ascorbic acid, nicotinic acid, isonicotinic acid, methane or ethanesulfonic acid,
- Q sulfuric acid, nitric acid, hydrohalic acids such as hydrochloric acid or hydrobromic acid, phosphoric acids such as orthophosphoric
- Toluenesulfonic acid naphthalene mono- and disulfonic acids, lauryl sulfuric acid.
- Salts with physiologically unacceptable acids, e.g. Picrates can be used to isolate and / or purify the compounds of the
- compounds of formula I with bases can be converted into the corresponding metal, in particular alkali metal or alkaline earth metal, or into the corresponding ammonium salts.
- bases e.g. sodium or potassium hydroxide or carbonate
- organic bases e.g. Ethanolamine can be used.
- the pharmaceutical activity of the racemates or the stereoisomers of the compounds according to the invention can differ, it may be desirable to use the enantiomers.
- the end product or even the intermediates can be separated into enantiomeric compounds by chemical or physical measures known to the person skilled in the art or can already be used as such in the synthesis.
- diastereomers are formed from the mixture by reaction with an optically active release agent.
- Suitable release agents are, for example, optically active acids, such as the R and S forms of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, Malic acid, lactic acid, suitable N-protected amino acids (eg N-benzoylproline or N-benzenesulfonylproline) or the various optically active camphorsulfonic acids.
- an optically active separating agent for example dinitrobenzoylphenylglycine, cellulose triacetate or others
- Aqueous or alcoholic solvent mixtures such as e.g. Hexane / isopropanol / acetonitrile e.g. in the ratio 82: 15: 3.
- the invention further relates to the use of the compounds of the formula I and / or their physiologically acceptable salts for the production of pharmaceutical preparations, in particular by a non-chemical route. They can be brought into a suitable dosage form together with at least one solid, liquid and / or semi-liquid carrier or auxiliary and, if appropriate, in combination with one or more further active ingredients.
- the invention further relates to medicaments containing at least one compound of the formula I and / or its pharmaceutically usable derivatives, solvates and stereoisomers, including their mixtures in all ratios, and, if appropriate, carriers and / or auxiliaries.
- Suitable carriers are organic or inorganic substances which are suitable for enteral (e.g. oral), parenteral or topical application and do not react with the new compounds, for example water, vegetable oils, benzyl alcohols, alkylene glycols, polyethylene glycols, glycerol triacetate, gelatin, carbohydrates such as lactose or starch, magnesium stearate, talc, petroleum jelly. Tablets, pills, coated tablets,
- the new compounds can also be lyophilized and the lyophilizates obtained, for example for the preparation of
- Injectables are used.
- the specified preparations can be sterilized and / or auxiliary substances such as lubricants, preservatives,
- Contain flavor and / or several other active ingredients e.g. one or more vitamins.
- the compounds of the formula I and their physiologically acceptable salts can be used to combat and prevent thrombo-embolic diseases such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication, migraine, tumors, tumor diseases and / or tumor metastases can be used.
- thrombo-embolic diseases such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty and intermittent claudication, migraine, tumors, tumor diseases and / or tumor metastases can be used.
- the substances according to the invention are generally preferably administered in doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
- the daily doses between about 1 and 500 mg, in particular between 5 and 100 mg, per dosage unit.
- Dosage is preferably between about 0.02 and 10 mg / kg body weight.
- the specific dose for each patient depends on a variety of factors, for example on the effectiveness of the particular compound used, on the age, body weight, general health, sex, on the diet, on the time and route of administration, on the rate of elimination, combination of drugs and severity the respective disease to which the therapy applies. Oral application is preferred.
- the invention also relates to a set (kit) consisting of separate packs of
- the set contains suitable containers, such as boxes or boxes, individual bottles, bags or ampoules.
- the set can contain, for example, separate ampoules, each containing an effective amount of a compound of the .
- the invention furthermore relates to the use of compounds of the formula I and / or their pharmaceutically usable derivatives,
- Tumors, tumor diseases and / or tumor metastases in combination with at least one other drug ingredient.
- customary work-up means: if necessary, water is added, if necessary, depending on the constitution of the end product, the pH is adjusted to between 2 and 10, extracted with ethyl acetate or dichloromethane, and the mixture is dried and dried organic phase EP03 / 01177
- Step 2 9.2 g (21, 674 mmol) 4 are dissolved in 40.0 mL DCM, with 4.33 g
- Example A Injection glasses
- a solution of 100 g of an active ingredient of the formula I and 5 g of disodium hydrogenphosphate is adjusted to pH 6.5 in 3 l of double-distilled water with 2N hydrochloric acid, sterile filtered, filled into injection glasses, lyophilized under sterile conditions and sealed sterile. Each injection glass contains 5 mg of active ingredient.
- a mixture of 20 g of an active ingredient of the formula I is melted with 100 g of soy lecithin and 1400 g of cocoa butter, poured into molds and allowed to cool. Each suppository contains 20 mg of active ingredient.
- a solution of 1 g of an active ingredient is prepared of the formula I, 9.38 g of NaH 2 P0 4 • 2 H 2 0, 28.48 g Na 2 HP0 4 • 12 H 2 0 and 0.1 g of benzalkonium chloride in 940 ml of double distilled water. It is adjusted to pH 6.8, made up to 1 I and sterilized by irradiation. This solution can be used in the form of eye drops.
- Example D ointment
- 500 mg of an active ingredient of the formula I are mixed with 99.5 g of petroleum jelly under aseptic conditions.
- Example E tablets A mixture of 1 kg of active ingredient of the formula I, 4 kg of lactose, 1, 2 kg of potato starch, 0.2 kg of talc and 0.1 kg of magnesium stearate is compressed into tablets in a conventional manner such that each tablet contains 10 mg of active ingredient.
- Example F coated tablets
- Example E tablets are pressed, which are then coated in a conventional manner with a coating of sucrose, potato starch, talc, tragacanth and colorant.
- Example G capsules
- each capsule contains 20 mg of the active ingredient.
- a solution of 1 kg of active ingredient of the formula I in 60 l of double-distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03704559A EP1480948A1 (de) | 2002-03-04 | 2003-02-06 | Semicarbazidderivate und ihre verwendung als antithrombotika |
JP2003572950A JP2005519114A (ja) | 2002-03-04 | 2003-02-06 | セミカルバジド誘導体および抗血栓剤としてのこれらの使用 |
CA002478528A CA2478528A1 (en) | 2002-03-04 | 2003-02-06 | Semicarbazide derivatives and the use thereof as antithrombotics |
AU2003206852A AU2003206852A1 (en) | 2002-03-04 | 2003-02-06 | Semicarbazide derivatives and their use as antithrombotics |
MXPA04008479A MXPA04008479A (es) | 2002-03-04 | 2003-02-06 | Derivados de semicarbazida. |
KR10-2004-7013762A KR20040095256A (ko) | 2002-03-04 | 2003-02-06 | 세미카르바자이드 유도체 및 항혈전제로서의 이의 용도 |
US10/506,801 US20050119316A1 (en) | 2002-03-04 | 2003-02-06 | Semicarbazide derivatives and the use thereof as antithrombotics |
BR0308136-2A BR0308136A (pt) | 2002-03-04 | 2003-02-06 | Derivados de semicarbazida e o uso destes como antitrombóticos |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10209211 | 2002-03-04 | ||
DE10209211.7 | 2002-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003074479A1 true WO2003074479A1 (de) | 2003-09-12 |
Family
ID=27770932
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2003/001177 WO2003074479A1 (de) | 2002-03-04 | 2003-02-06 | Semicarbazidderivate und ihre verwendung als antithrombotika |
Country Status (14)
Country | Link |
---|---|
US (1) | US20050119316A1 (de) |
EP (1) | EP1480948A1 (de) |
JP (1) | JP2005519114A (de) |
KR (1) | KR20040095256A (de) |
CN (1) | CN1639115A (de) |
AR (1) | AR038621A1 (de) |
AU (1) | AU2003206852A1 (de) |
BR (1) | BR0308136A (de) |
CA (1) | CA2478528A1 (de) |
MX (1) | MXPA04008479A (de) |
PL (1) | PL371214A1 (de) |
RU (1) | RU2004129594A (de) |
WO (1) | WO2003074479A1 (de) |
ZA (1) | ZA200407903B (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100783585B1 (ko) | 2006-08-22 | 2007-12-07 | 한국생명공학연구원 | 스탯의 활성을 저해하는 옥사다이아졸 우레아 화합물을 유효성분으로 함유하는 암의 예방 또는 치료제 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016315A1 (de) * | 2000-08-21 | 2002-02-28 | Merck Patent Gmbh | AZA-AMINOSÄUREDERIVATE (FAKTOR Xa-INHIBITOREN 15) |
-
2003
- 2003-02-06 CA CA002478528A patent/CA2478528A1/en not_active Abandoned
- 2003-02-06 EP EP03704559A patent/EP1480948A1/de not_active Withdrawn
- 2003-02-06 WO PCT/EP2003/001177 patent/WO2003074479A1/de not_active Application Discontinuation
- 2003-02-06 PL PL03371214A patent/PL371214A1/xx unknown
- 2003-02-06 JP JP2003572950A patent/JP2005519114A/ja active Pending
- 2003-02-06 US US10/506,801 patent/US20050119316A1/en not_active Abandoned
- 2003-02-06 RU RU2004129594/04A patent/RU2004129594A/ru not_active Application Discontinuation
- 2003-02-06 BR BR0308136-2A patent/BR0308136A/pt not_active Application Discontinuation
- 2003-02-06 CN CNA038051443A patent/CN1639115A/zh active Pending
- 2003-02-06 AU AU2003206852A patent/AU2003206852A1/en not_active Abandoned
- 2003-02-06 MX MXPA04008479A patent/MXPA04008479A/es not_active Application Discontinuation
- 2003-02-06 KR KR10-2004-7013762A patent/KR20040095256A/ko not_active Application Discontinuation
- 2003-02-28 AR ARP030100659A patent/AR038621A1/es not_active Application Discontinuation
-
2004
- 2004-09-30 ZA ZA200407903A patent/ZA200407903B/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002016315A1 (de) * | 2000-08-21 | 2002-02-28 | Merck Patent Gmbh | AZA-AMINOSÄUREDERIVATE (FAKTOR Xa-INHIBITOREN 15) |
Also Published As
Publication number | Publication date |
---|---|
JP2005519114A (ja) | 2005-06-30 |
US20050119316A1 (en) | 2005-06-02 |
MXPA04008479A (es) | 2004-12-06 |
EP1480948A1 (de) | 2004-12-01 |
AR038621A1 (es) | 2005-01-19 |
BR0308136A (pt) | 2005-01-04 |
CA2478528A1 (en) | 2003-09-12 |
ZA200407903B (en) | 2005-07-04 |
KR20040095256A (ko) | 2004-11-12 |
AU2003206852A1 (en) | 2003-09-16 |
RU2004129594A (ru) | 2005-06-27 |
PL371214A1 (en) | 2005-06-13 |
CN1639115A (zh) | 2005-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE10102322A1 (de) | Phenylderivate | |
DE10112768A1 (de) | Phenylderivate 3 | |
EP1517685A1 (de) | 2-(phenyl)-2h-pyrazol-3-carbonsäure-n-4-(thioxo-heterocyclyl)-phenyl-amid derivate und entsprechende imino-heterocyclyl derivate sowie verwandte verbindungen als inhibitoren der koagulationsfaktoren xa und/oder viia zur behandlung von thrombosen | |
DE10117823A1 (de) | Oxalsäurederivate | |
WO2000051989A1 (de) | Pyrazol-3-on-derivate als faktor xa inhibitoren | |
EP1414456B1 (de) | Phenylderivate als faktor xa inhibitoren | |
DE10155075A1 (de) | Cyclische Sulfonamide | |
DE10214832A1 (de) | Phenylderivate 4 | |
WO2002074735A2 (de) | Biurethanderivate | |
WO2002006269A1 (de) | Cyclische aminosäurederivate | |
DE10302500A1 (de) | Carbonsäureamidderivate | |
WO2002008177A2 (de) | N-substituierte-1-amino-1,1-dialkylcarbonsäurederivate | |
WO2003093235A1 (de) | Carbonsäureamide als inhibitoren des koagulationsfaktors xa | |
EP1284961A1 (de) | Glycinamide | |
WO2003074479A1 (de) | Semicarbazidderivate und ihre verwendung als antithrombotika | |
DE10110325A1 (de) | Phenylderivate 2 | |
EP1309549A1 (de) | Acetamidderivate und ihre verwendung als inhibitoren des koagulationsfaktors xa und viia | |
EP1399449A1 (de) | Kohlenhydratderivate | |
WO2001092214A1 (de) | Carbaminsäureester als inhibitoren des faktors xa | |
EP1309573A1 (de) | Urethanderivate | |
DE10236868A1 (de) | Carbonsäureamide | |
DE10218974A1 (de) | Carnonsäureamide |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003704559 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2004/008479 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2478528 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047013762 Country of ref document: KR Ref document number: 2003572950 Country of ref document: JP Ref document number: 20038051443 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10506801 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004/07903 Country of ref document: ZA Ref document number: 200407903 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2004129594 Country of ref document: RU Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003206852 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047013762 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003704559 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003704559 Country of ref document: EP |